> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Merck Ending Keytruda Phase 3 Prostate Cancer Trial
- URL: https://www.fdaweb.com/merck-ending-keytruda-phase-3-prostate-cancer-trial/
- Published: 2023-01-25T12:00:00.000Z
- Updated: 2026-09-14T18:13:05.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153622

Merck says it is terminating a Phase 3 trial of its Keytruda (pembrolizumab) combined with enzalutamide (Astellas’ Xtandi) and androgen deprivation therapy to treat patients with metastatic hormone-sensitive prostate cancer. The company [says](https://www.merck.com/news/merck-announces-keynote-991-trial-evaluating-keytruda-pembrolizumab-plus-enzalutamide-and-androgen-deprivation-therapy-in-patients-with-metastatic-hormone-sensitive-prostate-cancer-to-stop-for/?ref=fdaweb.com) the decision to end the trial follows the recommendation of an independent data monitoring committee that reviewed data from a planned interim analysis and found the drugs did not demonstrate an improvement in overall survival or radiographic progression-free survival, the trial’s primary endpoints.